SCHEMBL21496595

SCHEMBL21496595

CC(C)N(CCCCCl)c1cnc(-c2ccccc2)c(-c2ccccc2)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 2/20 0.68
ADORA3 P0DMS8 2/20 0.68
TBXA2R P21731 2/20 0.68
AGTR1 P30556 2/20 0.68
PTGIR P43119 2/20 0.68
PDE4D Q08499 2/20 0.68
PTGDR Q13258 2/20 0.68
DRD1 P21728 1/20 0.68
CKS1B P61024 6/20 0.60
SKP1 P63208 6/20 0.60
SKP2 Q13309 6/20 0.60
CNR1 P21554 3/20 0.60
ABCB11 O95342 1/20 0.60
HTR1A P08908 1/20 0.60
HTR2A P28223 1/20 0.60
ADRA1A P35348 1/20 0.60
OPRD1 P41143 1/20 0.60
OPRK1 P41145 1/20 0.60
HTR2B P41595 1/20 0.60
SCN5A Q14524 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19820820 0.90 NR1I2 (0.68) NR1I2ADORA3TBXA2RAGTR1PTGIR
SCHEMBL3697913 0.88 NR1I2 (0.70) NR1I2ADORA3TBXA2RAGTR1PTGIR
SCHEMBL29479211 0.88 NR1I2 (0.70) NR1I2ADORA3TBXA2RAGTR1PTGIR
SCHEMBL2132049 0.88 NR1I2 (0.70) NR1I2ADORA3TBXA2RAGTR1PTGIR
SCHEMBL5211665 0.88 NR1I2 (0.67) NR1I2ADORA3TBXA2RAGTR1PTGIR
SCHEMBL18584837 0.88 NR1I2 (0.66) NR1I2ADORA3TBXA2RAGTR1PTGIR
SCHEMBL19823721 0.87 NR1I2 (0.72) NR1I2ADORA3TBXA2RAGTR1PTGIR
SCHEMBL22819616 0.84 NR1I2 (0.65) NR1I2ADORA3TBXA2RAGTR1PTGIR
Acetic Acid SCHEMBL29068588 0.84 NR1I2 (0.71) NR1I2ADORA3TBXA2RAGTR1PTGIR
SCHEMBL18630467 0.84 NR1I2 (0.65) NR1I2ADORA3TBXA2RAGTR1PTGIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035352-A1 Inhibitors of Platelet Function and Methods for Use of the Same UNIV MICHIGAN REGENTS (US) 2026-02-05 US disclosed
US-12269805-B2 Inhibitors of platelet function and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2025-04-08 US disclosed
CN-113015725-B Platelet function inhibitors and methods of use thereof 密歇根大学董事会 2024-08-13 CN disclosed
US-20230140210-A1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-05-04 US disclosed
US-20230140210-A1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-05-04 US disclosed
EP-3781558-B1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME UNIV MICHIGAN REGENTS (US) 2023-03-01 EP disclosed
US-11498905-B2 Inhibitors of platelet function and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2022-11-15 US disclosed
US-20210363113-A1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-11-25 US disclosed
US-20210363113-A1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-11-25 US disclosed
CN-113015725-A Platelet function inhibitors and methods of use thereof 密歇根大学董事会 2021-06-22 CN disclosed
EP-3781558-A1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME The Regents Of The University Of Michigan (US) 2021-02-24 EP disclosed
WO-2019204447-A1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-10-24 WO disclosed
WO-2019204447-A1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035352-A1 Inhibitors of Platelet Function and Methods for Use of the Same TFPI, MPL, PF4 NR1I2 4716/4885ADORA3 1804/4885TBXA2R 91/4885
US-12269805-B2 Inhibitors of platelet function and methods for use of the same TFPI, F2, TFPI2 NR1I2 2666/4885ADORA3 2114/4885TBXA2R 22/4885
US-11498905-B2 Inhibitors of platelet function and methods for use of the same TFPI, F2, TFPI2 NR1I2 2666/4885ADORA3 2114/4885TBXA2R 22/4885
US-20210363113-A1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME TFPI, F2, TFPI2 NR1I2 2666/4885ADORA3 2114/4885TBXA2R 22/4885
US-20230140210-A1 INHIBITORS OF PLATELET FUNCTION AND METHODS FOR USE OF THE SAME TFPI, F2, TFPI2 NR1I2 2666/4885ADORA3 2114/4885TBXA2R 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.